William Wood
Stock Analyst at B. Riley Securities
(3.69)
# 2,208
Out of 4,604 analysts
54
Total ratings
53.3%
Success rate
11.5%
Average return
Main Sectors:
Stocks Rated by William Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintained: Buy | $55 → $86 | $49.88 | +72.41% | 2 | Jul 27, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $34 | $14.32 | +137.43% | 1 | Jul 23, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $31 | $18.65 | +66.22% | 1 | Jul 17, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $85 | $33.51 | +153.66% | 1 | Jun 25, 2026 | |
| PALI Palisade Bio | Reiterated: Buy | $7 | $2.12 | +230.19% | 2 | Jun 2, 2026 | |
| EQ Equillium | Reiterated: Buy | $6 | $2.19 | +173.97% | 2 | Jun 2, 2026 | |
| IMUX Immunic | Maintained: Buy | $50 → $27 | $14.01 | +92.72% | 10 | May 22, 2026 | |
| AARD Aardvark Therapeutics | Maintained: Buy | $8 → $7 | $7.52 | -6.91% | 3 | May 15, 2026 | |
| ALT Altimmune | Maintained: Buy | $13 | $3.03 | +329.04% | 1 | Mar 6, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $560 → $670 | $514.12 | +30.32% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.57 | +218.47% | 1 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $1.06 | +183.02% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $2.33 | n/a | 7 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $11 | $3.68 | n/a | 10 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $13.16 | n/a | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $4.13 | n/a | 4 | May 2, 2024 |
TG Therapeutics
Jul 27, 2026
Maintained: Buy
Price Target: $55 → $86
Current: $49.88
Upside: +72.41%
AgomAb Therapeutics NV
Jul 23, 2026
Initiated Coverage: Buy
Price Target: $34
Current: $14.32
Upside: +137.43%
Trevi Therapeutics
Jul 17, 2026
Reiterated: Buy
Price Target: $31
Current: $18.65
Upside: +66.22%
Viking Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $85
Current: $33.51
Upside: +153.66%
Palisade Bio
Jun 2, 2026
Reiterated: Buy
Price Target: $7
Current: $2.12
Upside: +230.19%
Equillium
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $2.19
Upside: +173.97%
Immunic
May 22, 2026
Maintained: Buy
Price Target: $50 → $27
Current: $14.01
Upside: +92.72%
Aardvark Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $8 → $7
Current: $7.52
Upside: -6.91%
Altimmune
Mar 6, 2026
Maintained: Buy
Price Target: $13
Current: $3.03
Upside: +329.04%
Madrigal Pharmaceuticals
Dec 11, 2025
Maintained: Buy
Price Target: $560 → $670
Current: $514.12
Upside: +30.32%
Dec 8, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.57
Upside: +218.47%
Nov 21, 2025
Maintained: Buy
Price Target: $3
Current: $1.06
Upside: +183.02%
Feb 11, 2025
Reiterated: Buy
Price Target: $50
Current: $2.33
Upside: n/a
Aug 8, 2024
Maintained: Buy
Price Target: $12 → $11
Current: $3.68
Upside: n/a
May 8, 2024
Reiterated: Buy
Price Target: $10
Current: $13.16
Upside: n/a
May 2, 2024
Maintained: Buy
Price Target: $4
Current: $4.13
Upside: n/a